GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Imexpharm Corp (STC:IMP) » Definitions » Cyclically Adjusted Price-to-FCF

Imexpharm (STC:IMP) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Imexpharm Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imexpharm Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Imexpharm's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imexpharm Cyclically Adjusted Price-to-FCF Chart

Imexpharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 400.90 -

Imexpharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 202.60 1,442.88 - - -

Competitive Comparison of Imexpharm's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imexpharm's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Imexpharm's Cyclically Adjusted Price-to-FCF falls into.



Imexpharm Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Imexpharm's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Imexpharm's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-484.835/131.7762*131.7762
=-484.835

Current CPI (Mar. 2024) = 131.7762.

Imexpharm Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 601.505 100.560 788.230
201409 122.423 100.428 160.637
201412 -110.754 99.070 -147.318
201503 -135.345 99.621 -179.031
201506 60.063 100.684 78.611
201509 -362.491 100.392 -475.814
201512 1,319.601 99.792 1,742.538
201603 -559.900 100.470 -734.361
201606 824.063 101.688 1,067.892
201609 -1,428.701 101.861 -1,848.291
201612 575.603 101.863 744.637
201703 -2,203.650 102.862 -2,823.084
201706 -695.266 103.349 -886.505
201709 -217.773 104.136 -275.576
201712 63.064 104.011 79.899
201803 -2,818.101 105.290 -3,527.024
201806 -749.464 106.317 -928.936
201809 141.413 106.507 174.964
201812 1,111.621 105.998 1,381.963
201903 -1,913.459 107.251 -2,351.023
201906 43.058 108.070 52.503
201909 215.087 108.329 261.640
201912 737.170 108.420 895.973
202003 -346.788 108.902 -419.631
202006 122.123 108.767 147.957
202009 -1,101.128 109.815 -1,321.337
202012 1,296.128 109.897 1,554.175
202103 412.429 111.754 486.319
202106 492.580 114.631 566.253
202109 158.014 115.734 179.916
202112 1,448.221 117.630 1,622.391
202203 1,010.990 121.301 1,098.296
202206 1,036.749 125.017 1,092.804
202209 486.678 125.227 512.133
202212 1,184.994 125.222 1,247.019
202303 -717.964 127.348 -742.931
202306 -780.375 128.729 -798.849
202309 -874.566 129.860 -887.474
202312 1,192.149 129.419 1,213.859
202403 -484.835 131.776 -484.835

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imexpharm  (STC:IMP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Imexpharm Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Imexpharm's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Imexpharm (STC:IMP) Business Description

Industry
Traded in Other Exchanges
N/A
Address
4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. Its products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.

Imexpharm (STC:IMP) Headlines

No Headlines